Articles from Komodo Health

Healthcare technology company Komodo Health announced today that Komodo Health and Blue Health Intelligence (BHI) have settled litigation resolving an ongoing dispute. The settlement dismisses the litigation with no admission or finding of liability by either party.

In response to the persistently high nationwide burden of colorectal cancer (CRC), Fight Colorectal Cancer (Fight CRC) has launched the Colorectal Cancer Care Initiative (CRCCI), a powerful collaboration aimed at mobilizing collective expertise and resources to tackle challenges in CRC screening, diagnosis, and treatment. Komodo Health is proud to be part of this diverse coalition — which includes survivors, caregivers, healthcare providers, researchers, and industry leaders — united to drive meaningful progress against the second-leading cause of cancer death among men and women combined.

Healthcare technology company Komodo Health today announced the recipients of the 2024 Diet-Related Health (DRH) grant. Through the DHR program, which is funded by the Robert Wood Johnson Foundation (RWJF), selected researchers gain free access to Komodo’s Healthcare Map™, the industry’s largest and most complete repository of de-identified real-world patient analytics and insights, to study the impact of diet on health and advance new research to inform strategies that will mitigate disease incidence, increase health equity, and improve patient outcomes.

Healthcare technology company Komodo Health today launches a new product, National Drug Projections, bringing its customers a clear, complete, and detailed view of how many prescriptions are filled across the country for any group of medications. The new solution unlocks real-time market landscape intelligence, such as prescription volume, units dispensed, and new patient starts, to deliver an in-depth understanding of treatment dynamics that can better inform revenue forecasts, market share tracking, marketing resourcing, salesforce sizing, and more.

Healthcare technology company Komodo Health today announced the appointment of Daniel Brox as its new General Manager, Analytics Consulting. With over 22 years of experience at ZS Associates, as well as extensive client-side experience, Daniel brings a wealth of expertise in driving growth, strategy, and impact across the Life Sciences industry. In his new role at Komodo, Daniel will work closely with the company’s executive leadership team to spearhead the next phase of growth in Analytics Consulting capabilities, with a focus on expanding Komodo’s market presence and enhancing customer engagement.

Healthcare technology company Komodo Health today introduces two new products within its MapLab platform, making it easier than ever before to tap into the industry’s most robust database of de-identified patient-level insights. With the launch of MapAI™ and MapExplorer™, Komodo deepens its commitment to improving the insights workflow, applying AI-enabled tools to rapidly produce targeted, trustworthy and contextualized insights and analyses. Both offerings are available in MapLab, the industry's only unified suite of applications designed to accelerate and democratize insight generation for healthcare and Life Sciences organizations.

Komodo Health, the leader in healthcare technology and data-driven insights, has been named to the Forbes 2024 Cloud 100, the definitive ranking of the top 100 private cloud companies in the world, published by Forbes in partnership with Bessemer Venture Partners and Salesforce Ventures. As Komodo Health nears a decade of providing leading technology to Life Sciences and enabling patient-centric insights at scale, its fourth Forbes Cloud 100 honor reinforces the company’s influence and impact on reshaping the healthcare landscape through its end-to-end AI-powered platform.

Komodo Health, a leader in healthcare technology and data-driven intelligence, today announces the appointment of Miles Ennis as Chief Revenue Officer (CRO). In this new role, he will join Komodo’s executive leadership team, overseeing the company's commercial operations. Ennis will lead revenue and account management efforts for Komodo’s broad portfolio of customers to support the expanding impact of the company’s technology platform across Healthcare and Life Sciences organizations.

Healthcare technology company Komodo Health today announced the appointment of Julia Goebel as Chief Marketing Officer (CMO). As a member of the company’s executive leadership team, Julia supports overall corporate strategy and spearheads market expansion. With healthcare and Life Sciences companies increasing their reliance on Komodo for enterprise insights, Julia brings a renewed focus on how the company’s data-driven insights, platform, and AI software solutions address industry workflow challenges to reduce the burden of disease.

Today, Komodo Health launches Komodo Patient Insurance™ (KPI), a first-of-its-kind data offering featuring in-depth insights into the insurance status of more than 200 million de-identified U.S. patient lives. With this news, Komodo introduces the most comprehensive resource to accurately identify a patient's pharmacy and medical insurance enrollment status, including primary and secondary payer details across channel, segment, payer and geography. Commercial, Market Access, Medical Affairs, and HEOR teams will use KPI to quickly unlock answers to common business questions around patient enrollment and payer mapping.

Today, Komodo Health announced a series of updates to its MapEnhanceTM offering, increasing the depth and volume of insights into social determinants of health (SDOH). The company also introduced two new specialty data partners, GeneDx and COTA Healthcare. With this news, companies can tap into Komodo’s fully integrated analytics solution to access the industry’s most complete view of clinical encounters and gain a more holistic understanding of the social and environmental factors that may impact patient outcomes.

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform. The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases that have significant unmet patient needs.

Today, Komodo Health unveiled a new self-service solution for rapid patient cohort analysis and insight generation. MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map. MapView is designed to accelerate decision-making across the Life Sciences enterprise by generating powerful, automated business intelligence for every team and at every stage of the Life Sciences product life cycle, from clinical development and medical strategy to commercialization.

Komodo Health today unveiled findings from a new, first-of-its kind survey detailing the challenges to obtaining data-driven insights that continue to impede progress across the U.S. Life Sciences organizations. Conducted independently by Frost & Sullivan, the new blinded survey benchmarks the current state of real-world data (RWD) and analytics, exposing the complexities that teams face in generating meaningful insights — as reported by Life Sciences leaders, middle managers, and data scientists/analysts.

Komodo Health, in collaboration with the Robert Wood Johnson Foundation (RWJF) and Mathematica, today announces a new program that will fund innovative studies to explore the impact of diet-related diseases across the country. As part of this news, the Diet-Related Health (DRH) Research Program is launching a competitive call for proposals, seeking new research projects focused on the impact of diet on health to accelerate new strategies for improving nutrition, preventing childhood obesity, and advancing diet-related health equity in the U.S.

Today, Komodo Health announces the expansion of its enterprise engagement capabilities and launches a new, dedicated Enterprise Strategy and Transformation team. As data, technology, and AI continue to accelerate breakthrough innovation and drive efficiency across Healthcare and Life Sciences, this team will help Komodo identify new opportunities to deliver patient impact as the technology partner of choice among the world’s top healthcare and Life Sciences teams. In collaboration with Komodo’s Professional Services group, the Enterprise Strategy and Transformation team will help connect healthcare stakeholders with a portfolio of solutions that can be configured to support a range of objectives, from medical information dissemination to direct-to-patient services and engagement.

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy is joining forces with Komodo Health as its data and technology partner to drive comparative outcomes and cost-effectiveness research and analytics. The CHOICE Institute envisions using Komodo’s technology to unlock high-quality insights into healthcare utilization, costs, and outcomes in the United States, working toward its vision of generating knowledge to improve individual and population health.

Komodo Health today announced a significant expansion of its Healthcare Map, integrating an additional 90 million annual closed patient lives from an array of new partnerships. This expansion further cements Komodo's position as the leader in healthcare data and analytics, offering Healthcare and Life Sciences companies unprecedented opportunities to accelerate precision insights for commercially and publicly insured patient populations.

Komodo Health today announced it has been awarded a CMS Innovator’s License, giving the company access to de-identified Medicare claims, Medicaid claims, and Medicare Advantage encounter data, which will greatly advance its already-robust health services research program. With the Innovator’s License, Komodo will now be able to infuse insights derived from its Innovator research program directly into its Healthcare Map, AI-powered technology platform, and suite of software applications. Komodo’s customers will now be able to derive even more nuanced insights that reflect the entire CMS patient population, alongside Komodo’s unparalleled view into commercial claims and other sources.

Komodo Health, a leading healthcare technology company, today announced the addition of two seasoned industry executives to leadership positions in the company. Julia Goebel was named Senior Vice President of Marketing, and Brad Kelley was named General Manager of MapEnhance. They join amid ongoing growth and momentum for Komodo’s data, platform, and software solutions, including the launch of Komodo’s new marquee offering, MapLabTM.

Komodo Health today introduced MapLab™, the first all-in-one offering for healthcare and Life Sciences companies to generate insights into disease trends, treatment pathways, patient populations, and a host of other complex research questions. The technology ushers in a new, fully integrated insights workflow solution for the industry to more easily and rapidly unearth rich insights that will help reduce disease burden at scale. MapLab includes robust data science tooling, customizable analytics dashboards, and a generative AI analytic assistant, delivered atop a unified, enterprise-wide platform and powered by Komodo’s best-in-class real-world patient data.

Komodo Health has been named to the 2023 Forbes Cloud 100, the definitive ranking of the top 100 private cloud companies in the world, published by Forbes in partnership with Bessemer Venture Partners and Salesforce Ventures. As healthcare and Life Sciences innovators continue to explore how to leverage workflow software and AI algorithms, Komodo has established healthcare’s next-generation analytics and insights platform, built on the journeys of more than 330 million U.S. patients. Komodo’s cloud-based technology is leveraged by healthcare and Life Sciences enterprises to turn de-identified data into insights that accelerate medical breakthroughs, expose gaps in care, and power high-quality real-world evidence research.

Komodo Health, a leading healthcare technology company, announced the appointment of Vikas Mehta as its new Chief Financial Officer (CFO) and Sarah Shin as the company’s new Chief People Officer (CPO). The two seasoned leaders will join Komodo’s executive team, where they will be responsible for implementing Komodo’s long-term growth and expansion strategy for their respective functions. The new executives join Komodo as the company continues to retain and grow its customer base across healthcare, digital health, and Life Sciences.

Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. Together, researchers representing Komodo Health, its customers, and its partners will present the results of research analyzing clinical and economic value across a wide range of therapeutic areas, including COVID-19, multiple sclerosis, prostate cancer, and more.

Komodo Health today unveils MapEnhance, a network of specialty data partners that seamlessly connects into Komodo’s technology platform. MapEnhance extends the insight-generating capacity of Komodo’s Healthcare Map by combining it with exclusive and highly informative data curated from Komodo’s partners. Available only through the Komodo platform, MapEnhance provides Komodo’s customers with access to a multidimensional, real-world view of clinical events and patient populations at a level of resolution not previously available.

Today, Komodo Health, a leading healthcare technology company, deepens its commitment to the White House Cancer Moonshot Initiative, joining patient advocates, industry innovators, federal policymakers, and public health officials to accelerate progress against colorectal cancer (CRC). During the meeting, Komodo will unveil new findings from its Healthcare Map supporting the need for earlier screening, which is especially urgent in light of pandemic-related impacts. While CRC screening rates have returned to the normal baseline, they have not made up for the 90% drop in colonoscopies seen in the spring of 2020, at the height of the pandemic.

Today, Komodo Health shares new details on its growing presence in the patient advocacy space, including new collaborations with advocacy organizations, expanded partnerships, and adoption of more technology solutions to meet the unique needs of patient-driven organizations. From defining rare diseases and identifying patients earlier, to helping patients find and educate providers, to improving clinical trial recruitment, Komodo is helping patient advocacy organizations address some of the biggest challenges patients face as they navigate their healthcare journeys. These partnerships empower advocacy organizations to harness data-driven strategies to support patients and reduce disease burden at scale.

Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodo’s platform. Intercept leveraged Komodo’s technology to fuel a retrospective study on long-term outcomes for Ocaliva, a therapeutic to treat primary biliary cholangitis (PBC), a rare liver disease. Results of the study focused on the real-world impact of Ocaliva and were announced last week at the American Association for the Study of Liver Diseases (AASLD).

Healthcare technology company Komodo Health today announced that Lauren Stahl has been appointed as the company’s Vice President and Head of Sales, effective immediately. In this capacity, Stahl’s responsibilities include sales team leadership across Komodo’s entire portfolio of customers, overseeing operational strategy to drive business efficiencies amid year-over-year growth and market expansion.

Today, Komodo Health announced a new partnership with the University of Maryland School of Pharmacy (UMSOP), providing its researchers and clinicians with access to Komodo’s technology platform and patient-level insights for a variety of population health research initiatives. UMSOP researchers will investigate disruption in access to healthcare services and treatment caused by the COVID-19 pandemic. This news follows a series of collaborations with leading health outcomes researchers from Pfizer, Stanford University, and more — leveraging Komodo’s technology to produce rich, actionable insights on the industry's most pressing challenges, ranging from COVID-19 to cardiovascular health to cell and gene therapy.

Today, Komodo Health announced that its platform will be used in studies led by Stanford Medicine focused on the short- and long-term health impacts of COVID-19. Researchers from Stanford’s Center for Population Health Sciences will utilize the Komodo Sentinel application, AI analytics tools, and de-identified patient data to investigate critical health challenges spanning infectious disease, pediatrics, surgery, population health, obstetrics and gynecology, and more. Initial research projects using Sentinel will explore the real-world impact of the COVID-19 pandemic on health outcomes among different patient populations, including disparities in care and social determinants of COVID-19 testing, COVID-19 vaccinations, and how cancer survival, treatment, and outcomes changed during the pandemic.

Today, Komodo Health will join advocacy leaders at Fight Colorectal Cancer (Fight CRC) and 17 other leading public health institutions and industry leaders at the White House to discuss solutions to improve colorectal cancer care standards in the U.S. The meeting is in response to President Biden’s call to action to improve and increase access to colorectal cancer screening, with a special emphasis on reaching underserved communities and closing gaps in care. The group of advocacy and industry experts will explore policy solutions and public-private partnerships that will advance the President’s Cancer Moonshot goals.

Turquoise Health and Komodo Health announced a partnership today to expand the depth of healthcare insights that power the Turquoise Clear Rates Data Platform. Building on Komodo technology, Turquoise Health is strengthening the power of its platform with intelligence from the Komodo Healthcare Map™. The partnership will equip Turquoise Health with information and insights to analyze patient journeys on a holistic basis to better understand the full constellation of costs associated with healthcare encounters. The combined breadth and depth of payment data for millions of patients will deliver greater visibility into healthcare prices and help simplify payer-provider contracts that will ultimately drive down costs for all stakeholders, including patients.

Komodo Health today announced that Dr. Aswin Chandrakantan has been appointed as the company’s first Chief Operating Officer, effective immediately. Dr. Chandrakantan will also retain his responsibilities as Komodo’s Chief Medical Officer.

Today at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference, Komodo Health showcased how its technology platform is powering the next generation of real-world evidence (RWE) research. With advanced analytics and technology applications like Sentinel, the company is partnering with a growing number of healthcare and Life Sciences companies to generate the industry’s most robust and nuanced insights, and drive a deeper understanding of the clinical and economic value of therapies.

Komodo Health today announced the launch of Komodo Publications Planning, introducing the next generation of publications planning and management applications for Life Sciences. The automated and highly customizable end-to-end software is designed to make it easier to maximize the impact and outcome of scientific publications and medical communications in an accurate, efficient, and compliant manner. With today’s news, Komodo extends the power of its real-world data and technology for Medical Affairs professionals, offering a comprehensive suite of applications to manage all aspects of publications planning, including a more data-driven approach to engaging with healthcare providers (HCPs).

Komodo Health today announced that its healthcare technology platform is being used by more than 40 customers who are leveraging the technology to build on Komodo. The platform enables healthcare, Life Sciences, and technology customers to drive innovation and create new machine-learning technologies that are built on intelligence from the company’s Healthcare Map. Komodo’s technology platform offers the industry’s first end-to-end, out-of-the-box capabilities for any stakeholder — from engineers to data scientists and analysts — to rapidly build solutions on a foundation of patient-centric insights.

Komodo Health today announced a new partnership with AppliedVR, the leader in therapeutic virtual reality (VR) for pain management. The FDA recently granted AppliedVR’s De Novo request for its flagship product, RelieVRx, and is now tapping into Komodo’s technology platform to further demonstrate the therapeutic impact of RelieVRx for patients living with chronic lower back pain. Using Komodo’s technology, AppliedVR will combine its proprietary insights with Komodo’s real-world data to conduct clinical research into the efficacy, cost savings, and health system value that RelieVRx delivers compared to traditional chronic pain treatment modalities.

Today, Komodo Health and Fight Colorectal Cancer (Fight CRC) expand their partnership with the introduction of the Fight CRC Provider Finder, a digital tool to help the colorectal cancer community simplify and accelerate how they identify colorectal cancer specialists across the U.S.

Komodo Health today announced it will be enabling rare disease patient advocacy organizations in the Chan Zuckerberg Initiative’s Rare As One Network with the software and analytics firepower needed to help improve earlier diagnoses, close gaps in care, and accelerate research across some of the world’s most complex and difficult diseases.

Komodo Health, a leader in software-driven health analytics, today announced the appointment of Edd Fleming, MD to its board of directors, further catalyzing the company’s role as the foundational enterprise technology and intelligence platform across the entire healthcare and life sciences ecosystem.

Komodo Health today announced the expansion of its Healthcare Map™, adding new demographic characteristics to help its customers advance health equity and close gaps in care through richer population health insights. Komodo’s Healthcare Map is the industry’s largest and most complete database of de-identified, real-world patient insights, providing a longitudinal view of encounters with the healthcare system for over 330 million patients.

During the HIMSS Global Conference, healthcare software company Komodo Health showcased its growing momentum in the market, as clients across the spectrum of healthcare and life sciences tap into the company’s powerful software solutions. Built on the company’s Healthcare Map™ of over 330 million real-world patient journeys, Komodo’s newest application, Sentinel, is driving differentiated impact, from optimizing clinical trial design to identifying gaps in care. Recent use cases at Janssen Research & Development LLC., PicnicHealth, and Klick Health underscore the versatility and power of Komodo’s software to deliver value across the entire life sciences enterprise.

Komodo Health today announced the acquisition of Breakaway Partners, a leading market access software company for the life sciences industry. The acquisition brings together Komodo’s Healthcare Map™ and software with Breakaway Partners’ industry-leading formulary data, policy criteria, and analytics platform to create the industry’s first enterprise market access solution suite based on a comprehensive, real-time view of real-world outcomes and costs.

Komodo Health announced today that Bill Madigan has been appointed as the company’s Chief Revenue Officer (CRO). With more than 25 years of experience commercializing software and services in healthcare and life sciences, Madigan will oversee Komodo’s customer-facing team and shape its commercial strategy.

PicnicHealth and Komodo Health today announced a partnership to support real-world evidence research programs for complex illnesses like multiple sclerosis and hemophilia. With this partnership, PicnicHealth will enrich its database of de-identified patient medical records with data from Komodo’s Healthcare Map™. The combined breadth and depth of real-world patient data will help support research efforts to close gaps in care, address unmet patient needs, and streamline clinical development efforts to deliver life-saving therapies to appropriate patients.

Komodo Health today announced the launch of two powerful software solutions that provide real-time intelligence in just a few clicks, tapping into 325 million real-world patient journeys for an unparalleled depth and breadth of insight. Prism and Sentinel allow stakeholders across Healthcare and Life Sciences to leverage the industry’s largest and most complete database of de-identified, real-world patient data – along with their own proprietary data – to develop insights and algorithms based on detailed patient behaviors and treatment patterns with an unprecedented level of precision, ease, and flexibility.